25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ONC (Beigene) Stock Analysis
Buy, Hold or Sell?

Let's analyze Beigene together

I guess you are interested in BeiGene, Ltd.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Beigene’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Beigene’s Price Targets

I'm going to help you getting a better view of BeiGene, Ltd.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BeiGene, Ltd.

I send you an email if I find something interesting about BeiGene, Ltd..

1. Quick Overview

1.1. Quick analysis of Beigene (30 sec.)










1.2. What can you expect buying and holding a share of Beigene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$33.64
Expected worth in 1 year
$64.67
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$31.03
Return On Investment
13.2%

For what price can you sell your share?

Current Price per Share
$235.94
Expected price per share
$172.67 - $287.88
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Beigene (5 min.)




Live pricePrice per Share (EOD)
$235.94
Intrinsic Value Per Share
$-25.25 - $7.99
Total Value Per Share
$8.40 - $41.63

2.2. Growth of Beigene (5 min.)




Is Beigene growing?

Current yearPrevious yearGrowGrow %
How rich?$3.3b$3.8b-$440.3m-13.1%

How much money is Beigene making?

Current yearPrevious yearGrowGrow %
Making money-$161.1m-$792.7m$631.5m391.8%
Net Profit Margin-18.0%-133.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Beigene (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#28 / 890

Most Revenue
#96 / 890

Most Profit
#638 / 890

Most Efficient
#425 / 890
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Beigene?

Welcome investor! Beigene's management wants to use your money to grow the business. In return you get a share of Beigene.

First you should know what it really means to hold a share of Beigene. And how you can make/lose money.

Speculation

The Price per Share of Beigene is $235.94. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Beigene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Beigene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $33.64. Based on the TTM, the Book Value Change Per Share is $7.76 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Beigene.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.53-0.6%-1.56-0.7%-0.59-0.2%-1.01-0.4%-0.74-0.3%-0.44-0.2%
Usd Book Value Change Per Share0.820.3%7.763.3%-0.16-0.1%2.381.0%1.620.7%0.840.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.820.3%7.763.3%-0.16-0.1%2.381.0%1.620.7%0.840.4%
Usd Price Per Share184.71-177.07-188.52-180.63-217.45-148.26-
Price to Earnings Ratio-30.11--31.45--25.31--47.58--6.39--53.95-
Price-to-Total Gains Ratio224.09--335.60--1,472.97--766.62--868.60--643.81-
Price to Book Ratio5.49-5.41-67.37-40.10-58.11-57.06-
Price-to-Total Gains Ratio224.09--335.60--1,472.97--766.62--868.60--643.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share235.94
Number of shares4
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share7.761.62
Usd Total Gains Per Share7.761.62
Gains per Quarter (4 shares)31.036.48
Gains per Year (4 shares)124.1125.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1012411402616
2024823805242
3037236207868
40496486010494
506216100130120
607457340156146
708698580181172
809939820207198
90111711060233224
100124112300259250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%3.037.00.07.5%3.041.00.06.8%
Book Value Change Per Share3.01.00.075.0%3.09.00.025.0%6.014.00.030.0%12.027.01.030.0%13.027.04.029.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share3.01.00.075.0%3.09.00.025.0%6.014.00.030.0%12.027.01.030.0%13.027.04.029.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BeiGene, Ltd. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8247.757-89%-0.159+119%2.382-65%1.620-49%0.840-2%
Book Value Per Share--33.64332.710+3%2.796+1103%13.093+157%9.175+267%5.117+557%
Current Ratio--1.8021.948-7%3.091-42%3.204-44%4.232-57%5.877-69%
Debt To Asset Ratio--0.4370.416+5%0.337+30%0.349+25%0.334+31%0.334+31%
Debt To Equity Ratio--0.7770.714+9%0.513+52%0.547+42%0.511+52%0.460+69%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--18333619486.00018531009497.570-1%258609091051.123-93%172285928710.844-89%232886951998.913-92%160129635329.803-89%
Eps---1.533-1.563+2%-0.587-62%-1.010-34%-0.737-52%-0.436-72%
Ev To Ebitda Ratio---157.079-85.533-46%-286.069+82%-170.076+8%-92.772-41%-108.717-31%
Ev To Sales Ratio--4.0644.920-17%110.898-96%95.679-96%298.217-99%738.241-99%
Free Cash Flow Per Share---0.175-1.607+819%-0.322+84%-0.765+337%-0.595+240%-0.361+107%
Free Cash Flow To Equity Per Share---0.221-1.144+419%-0.245+11%-0.586+166%-0.097-56%-0.004-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--7.986----------
Intrinsic Value_10Y_min---25.247----------
Intrinsic Value_1Y_max---1.122----------
Intrinsic Value_1Y_min---2.989----------
Intrinsic Value_3Y_max---1.905----------
Intrinsic Value_3Y_min---8.636----------
Intrinsic Value_5Y_max---0.923----------
Intrinsic Value_5Y_min---13.863----------
Market Cap23369054804.000+22%18294897486.00018261347247.570+0%257124529051.123-93%170593580127.511-89%230772543698.913-92%142808509146.823-87%
Net Profit Margin---0.135-0.180+34%-1.333+890%-1.576+1071%-2.412+1691%-5.085+3676%
Operating Margin---0.070-0.163+132%-0.535+660%-0.658+834%-1.909+2610%-4.806+6725%
Operating Ratio--1.0701.163-8%1.535-30%1.658-35%2.909-63%5.735-81%
Pb Ratio7.013+22%5.4905.405+2%67.373-92%40.103-86%58.109-91%57.064-90%
Pe Ratio-38.466-28%-30.114-31.447+4%-25.306-16%-47.583+58%-6.392-79%-53.946+79%
Price Per Share235.940+22%184.710177.070+4%188.515-2%180.629+2%217.455-15%148.264+25%
Price To Free Cash Flow Ratio-337.313-28%-264.072-45.741-83%-162.221-39%-112.599-57%-52.419-80%-103.099-61%
Price To Total Gains Ratio286.238+22%224.086-335.602+250%-1472.971+757%-766.620+442%-868.603+488%-643.814+387%
Quick Ratio--1.5061.616-7%2.795-46%3.204-53%5.324-72%8.302-82%
Return On Assets---0.026-0.028+9%-0.136+430%-0.114+344%-0.096+275%-0.100+291%
Return On Equity---0.046-0.048+5%-0.220+382%-0.174+283%-0.145+219%-0.140+208%
Total Gains Per Share--0.8247.757-89%-0.159+119%2.382-65%1.620-49%0.840-2%
Usd Book Value--3332222000.0003373727750.000-1%3814106500.000-13%4081492250.000-18%3986381700.000-16%2360767050.000+41%
Usd Book Value Change Per Share--0.8247.757-89%-0.159+119%2.382-65%1.620-49%0.840-2%
Usd Book Value Per Share--33.64332.710+3%2.796+1103%13.093+157%9.175+267%5.117+557%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--18333619486.00018531009497.570-1%258609091051.123-93%172285928710.844-89%232886951998.913-92%160129635329.803-89%
Usd Eps---1.533-1.563+2%-0.587-62%-1.010-34%-0.737-52%-0.436-72%
Usd Free Cash Flow---17320000.000-167442000.000+867%-438428500.000+2431%-365766666.667+2012%-375763400.000+2070%-232921250.000+1245%
Usd Free Cash Flow Per Share---0.175-1.607+819%-0.322+84%-0.765+337%-0.595+240%-0.361+107%
Usd Free Cash Flow To Equity Per Share---0.221-1.144+419%-0.245+11%-0.586+166%-0.097-56%-0.004-98%
Usd Market Cap23369054804.000+22%18294897486.00018261347247.570+0%257124529051.123-93%170593580127.511-89%230772543698.913-92%142808509146.823-87%
Usd Price Per Share235.940+22%184.710177.070+4%188.515-2%180.629+2%217.455-15%148.264+25%
Usd Profit---151881000.000-161196500.000+6%-792764522.750+422%-712355973.667+369%-577926584.200+281%-336258817.100+121%
Usd Revenue--1127824000.000952560250.000+18%614694750.000+83%640411750.000+76%458504900.000+146%251120075.000+349%
Usd Total Gains Per Share--0.8247.757-89%-0.159+119%2.382-65%1.620-49%0.840-2%
 EOD+6 -2MRQTTM+21 -16YOY+24 -133Y+19 -185Y+17 -2010Y+17 -20

3.3 Fundamental Score

Let's check the fundamental score of BeiGene, Ltd. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-38.466
Price to Book Ratio (EOD)Between0-17.013
Net Profit Margin (MRQ)Greater than0-0.135
Operating Margin (MRQ)Greater than0-0.070
Quick Ratio (MRQ)Greater than11.506
Current Ratio (MRQ)Greater than11.802
Debt to Asset Ratio (MRQ)Less than10.437
Debt to Equity Ratio (MRQ)Less than10.777
Return on Equity (MRQ)Greater than0.15-0.046
Return on Assets (MRQ)Greater than0.05-0.026
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of BeiGene, Ltd. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.065
Ma 20Greater thanMa 50242.306
Ma 50Greater thanMa 100249.326
Ma 100Greater thanMa 200228.949
OpenGreater thanClose236.280
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About BeiGene, Ltd.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Fundamental data was last updated by Penke on 2025-05-07 19:37:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Beigene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Beigene to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -13.5%Β means thatΒ $-0.13 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BeiGene, Ltd.:

  • The MRQ is -13.5%. The company is making a huge loss. -2
  • The TTM is -18.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-18.0%+4.5%
TTM-18.0%YOY-133.3%+115.3%
TTM-18.0%5Y-241.2%+223.2%
5Y-241.2%10Y-508.5%+267.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.5%-91.8%+78.3%
TTM-18.0%-183.9%+165.9%
YOY-133.3%-195.7%+62.4%
3Y-157.6%-245.0%+87.4%
5Y-241.2%-351.3%+110.1%
10Y-508.5%-492.7%-15.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Beigene is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Beigene to theΒ Biotechnology industry mean.
  • -2.6% Return on Assets means thatΒ Beigene generatedΒ $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BeiGene, Ltd.:

  • The MRQ is -2.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.6%TTM-2.8%+0.2%
TTM-2.8%YOY-13.6%+10.8%
TTM-2.8%5Y-9.6%+6.8%
5Y-9.6%10Y-10.0%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.6%-11.3%+8.7%
TTM-2.8%-11.5%+8.7%
YOY-13.6%-11.5%-2.1%
3Y-11.4%-11.9%+0.5%
5Y-9.6%-12.5%+2.9%
10Y-10.0%-14.2%+4.2%
4.3.1.3. Return on Equity

Shows how efficient Beigene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Beigene to theΒ Biotechnology industry mean.
  • -4.6% Return on Equity means Beigene generated $-0.05Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BeiGene, Ltd.:

  • The MRQ is -4.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.6%TTM-4.8%+0.2%
TTM-4.8%YOY-22.0%+17.2%
TTM-4.8%5Y-14.5%+9.8%
5Y-14.5%10Y-14.0%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.6%-14.8%+10.2%
TTM-4.8%-15.2%+10.4%
YOY-22.0%-15.1%-6.9%
3Y-17.4%-17.6%+0.2%
5Y-14.5%-18.1%+3.6%
10Y-14.0%-20.1%+6.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BeiGene, Ltd..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Beigene is operatingΒ .

  • Measures how much profit Beigene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Beigene to theΒ Biotechnology industry mean.
  • An Operating Margin of -7.0%Β means the company generated $-0.07 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BeiGene, Ltd.:

  • The MRQ is -7.0%. The company is operating very inefficient. -2
  • The TTM is -16.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-7.0%TTM-16.3%+9.3%
TTM-16.3%YOY-53.5%+37.2%
TTM-16.3%5Y-190.9%+174.5%
5Y-190.9%10Y-480.6%+289.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.0%-176.2%+169.2%
TTM-16.3%-282.8%+266.5%
YOY-53.5%-211.1%+157.6%
3Y-65.8%-249.1%+183.3%
5Y-190.9%-360.9%+170.0%
10Y-480.6%-476.2%-4.4%
4.3.2.2. Operating Ratio

Measures how efficient Beigene is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.07 means that the operating costs are $1.07 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BeiGene, Ltd.:

  • The MRQ is 1.070. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.163. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.070TTM1.163-0.093
TTM1.163YOY1.535-0.372
TTM1.1635Y2.909-1.745
5Y2.90910Y5.735-2.827
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0702.181-1.111
TTM1.1633.063-1.900
YOY1.5353.051-1.516
3Y1.6583.660-2.002
5Y2.9094.854-1.945
10Y5.7356.545-0.810
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BeiGene, Ltd..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Beigene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.80Β means the company has $1.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BeiGene, Ltd.:

  • The MRQ is 1.802. The company is able to pay all its short-term debts. +1
  • The TTM is 1.948. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.802TTM1.948-0.145
TTM1.948YOY3.091-1.143
TTM1.9485Y4.232-2.284
5Y4.23210Y5.877-1.645
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8023.588-1.786
TTM1.9483.930-1.982
YOY3.0914.298-1.207
3Y3.2044.804-1.600
5Y4.2325.817-1.585
10Y5.8776.197-0.320
4.4.3.2. Quick Ratio

Measures if Beigene is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Beigene to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.51Β means the company can pay off $1.51 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BeiGene, Ltd.:

  • The MRQ is 1.506. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.616. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.506TTM1.616-0.110
TTM1.616YOY2.795-1.179
TTM1.6165Y5.324-3.708
5Y5.32410Y8.302-2.978
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5062.768-1.262
TTM1.6163.419-1.803
YOY2.7954.136-1.341
3Y3.2044.675-1.471
5Y5.3245.993-0.669
10Y8.3026.549+1.753
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BeiGene, Ltd..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of BeigeneΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Beigene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.44Β means that Beigene assets areΒ financed with 43.7% credit (debt) and the remaining percentage (100% - 43.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of BeiGene, Ltd.:

  • The MRQ is 0.437. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.416. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.437TTM0.416+0.021
TTM0.416YOY0.337+0.079
TTM0.4165Y0.334+0.083
5Y0.33410Y0.334-0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4370.342+0.095
TTM0.4160.342+0.074
YOY0.3370.331+0.006
3Y0.3490.330+0.019
5Y0.3340.359-0.025
10Y0.3340.382-0.048
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Beigene is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Beigene to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 77.7% means that company has $0.78 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BeiGene, Ltd.:

  • The MRQ is 0.777. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.714. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.777TTM0.714+0.063
TTM0.714YOY0.513+0.202
TTM0.7145Y0.511+0.203
5Y0.51110Y0.460+0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7770.408+0.369
TTM0.7140.427+0.287
YOY0.5130.409+0.104
3Y0.5470.430+0.117
5Y0.5110.447+0.064
10Y0.4600.497-0.037
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Beigene generates.

  • Above 15 is considered overpriced butΒ always compareΒ Beigene to theΒ Biotechnology industry mean.
  • A PE ratio of -30.11 means the investor is paying $-30.11Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BeiGene, Ltd.:

  • The EOD is -38.466. Based on the earnings, the company is expensive. -2
  • The MRQ is -30.114. Based on the earnings, the company is expensive. -2
  • The TTM is -31.447. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-38.466MRQ-30.114-8.352
MRQ-30.114TTM-31.447+1.333
TTM-31.447YOY-25.306-6.141
TTM-31.4475Y-6.392-25.055
5Y-6.39210Y-53.946+47.554
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-38.466-1.711-36.755
MRQ-30.114-2.407-27.707
TTM-31.447-2.998-28.449
YOY-25.306-3.336-21.970
3Y-47.583-4.009-43.574
5Y-6.392-6.310-0.082
10Y-53.946-6.909-47.037
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BeiGene, Ltd.:

  • The EOD is -337.313. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -264.072. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -45.741. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-337.313MRQ-264.072-73.241
MRQ-264.072TTM-45.741-218.331
TTM-45.741YOY-162.221+116.480
TTM-45.7415Y-52.419+6.678
5Y-52.41910Y-103.099+50.681
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-337.313-2.379-334.934
MRQ-264.072-3.217-260.855
TTM-45.741-3.893-41.848
YOY-162.221-4.283-157.938
3Y-112.599-5.416-107.183
5Y-52.419-8.278-44.141
10Y-103.099-9.340-93.759
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Beigene is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 5.49 means the investor is paying $5.49Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BeiGene, Ltd.:

  • The EOD is 7.013. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.490. Based on the equity, the company is overpriced. -1
  • The TTM is 5.405. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.013MRQ5.490+1.523
MRQ5.490TTM5.405+0.085
TTM5.405YOY67.373-61.968
TTM5.4055Y58.109-52.704
5Y58.10910Y57.064+1.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.0131.696+5.317
MRQ5.4902.127+3.363
TTM5.4052.375+3.030
YOY67.3732.480+64.893
3Y40.1032.757+37.346
5Y58.1093.702+54.407
10Y57.0644.299+52.765
4.6.2. Total Gains per Share

2.4. Latest News of BeiGene, Ltd.

Does BeiGene, Ltd. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from BeiGene, Ltd. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-05-08
19:00
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...Read
2025-04-23
21:47
Why Is Summit Therapeutics Stock Soaring On Wednesday?Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BeiGene, Ltd..

4.8.3. Insider Transactions

Insiders are holding 19.167% of the shares of BeiGene, Ltd..

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-14Xiaodong WangSELL41760242.66
2025-04-01Xiaobin WuSELL51921281.4
2025-03-18Xiaodong WangSELL41760261.28
2025-03-07John OylerSELL58590249.13
2025-03-05Xiaobin WuSELL51921261.59
2025-03-04Xiaodong WangSELL8146254.58
2025-03-03John OylerSELL101000244.3
2025-02-28Bros. Advisors Lp BakerSELL732827260
2025-02-21Chan Henry LeeSELL1202258.04
2025-02-21Lai WangSELL5000257.23
2025-02-20Xiaobin WuSELL21267240.07
2025-02-18Xiaobin WuSELL30654240.74
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Total Other Income Expense Net 33,023-15,10117,922-16,6811,24120,72021,961-27,887-5,926



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,920,910
Total Liabilities2,588,688
Total Stockholder Equity3,332,222
 As reported
Total Liabilities 2,588,688
Total Stockholder Equity+ 3,332,222
Total Assets = 5,920,910

Assets

Total Assets5,920,910
Total Current Assets3,991,593
Long-term Assets1,929,317
Total Current Assets
Cash And Cash Equivalents 2,627,410
Net Receivables 709,106
Inventory 494,986
Other Current Assets 160,091
Total Current Assets  (as reported)3,991,593
Total Current Assets  (calculated)3,991,593
+/-0
Long-term Assets
Property Plant Equipment 1,657,238
Long Term Investments 128,933
Intangible Assets 129,765
Long-term Assets Other 13,381
Long-term Assets  (as reported)1,929,317
Long-term Assets  (calculated)1,929,317
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,214,899
Long-term Liabilities373,789
Total Stockholder Equity3,332,222
Total Current Liabilities
Short-term Debt 869,105
Short Long Term Debt 851,529
Accounts payable 404,997
Other Current Liabilities 879,963
Total Current Liabilities  (as reported)2,214,899
Total Current Liabilities  (calculated)3,005,594
+/- 790,695
Long-term Liabilities
Long term Debt 166,484
Capital Lease Obligations 61,853
Long-term Liabilities Other 70,498
Long-term Liabilities  (as reported)373,789
Long-term Liabilities  (calculated)298,835
+/- 74,954
Total Stockholder Equity
Common Stock138
Retained Earnings -8,606,836
Accumulated Other Comprehensive Income -148,988
Other Stockholders Equity 12,087,908
Total Stockholder Equity (as reported)3,332,222
Total Stockholder Equity (calculated)3,332,222
+/-0
Other
Capital Stock138
Cash and Short Term Investments 2,627,410
Common Stock Shares Outstanding 8,174
Liabilities and Stockholders Equity 5,920,910
Net Debt -1,547,544
Net Invested Capital 4,350,235
Net Working Capital 1,776,694
Property Plant and Equipment Gross 2,056,343
Short Long Term Debt Total 1,079,866



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
53,621
0
136,965
135,608
116,764
265,228
251,230
235,425
405,813
376,729
473,975
1,049,059
1,046,479
1,708,927
1,653,856
2,408,627
2,249,684
2,172,232
2,150,318
1,881,070
1,612,289
4,067,212
3,903,290
5,566,390
5,600,757
5,821,004
5,524,116
5,286,334
8,645,949
8,021,388
7,378,207
6,726,013
6,379,290
5,956,775
5,728,736
5,524,879
5,805,275
5,667,681
5,712,179
5,830,860
5,920,910
5,920,9105,830,8605,712,1795,667,6815,805,2755,524,8795,728,7365,956,7756,379,2906,726,0137,378,2078,021,3888,645,9495,286,3345,524,1165,821,0045,600,7575,566,3903,903,2904,067,2121,612,2891,881,0702,150,3182,172,2322,249,6842,408,6271,653,8561,708,9271,046,4791,049,059473,975376,729405,813235,425251,230265,228116,764135,608136,965053,621000
   > Total Current Assets 
0
0
0
47,188
44,395
130,200
128,211
106,269
251,782
232,754
209,953
374,399
336,178
418,691
962,330
913,497
1,585,702
1,516,707
2,180,195
1,943,842
1,796,730
1,755,680
1,435,550
1,172,696
3,595,187
3,392,404
4,965,736
4,960,690
5,140,979
4,799,039
4,432,835
7,613,880
6,948,139
6,345,876
5,749,168
4,713,456
4,704,318
4,401,419
4,053,542
4,203,414
3,907,750
3,839,022
3,911,736
3,991,593
3,991,5933,911,7363,839,0223,907,7504,203,4144,053,5424,401,4194,704,3184,713,4565,749,1686,345,8766,948,1397,613,8804,432,8354,799,0395,140,9794,960,6904,965,7363,392,4043,595,1871,172,6961,435,5501,755,6801,796,7301,943,8422,180,1951,516,7071,585,702913,497962,330418,691336,178374,399209,953232,754251,782106,269128,211130,20044,39547,188000
       Cash And Cash Equivalents 
0
0
0
13,898
-44,395
25,156
27,450
17,869
208,506
58,084
85,532
87,514
97,750
261,006
208,510
239,602
490,634
438,420
643,485
712,937
764,492
918,948
856,151
618,011
1,957,101
1,345,014
1,464,470
1,381,950
1,901,819
1,776,448
1,383,310
4,375,678
4,347,162
4,531,137
4,197,132
3,869,564
3,538,644
3,410,368
3,067,336
3,171,800
2,793,370
2,592,655
2,701,933
2,627,410
2,627,4102,701,9332,592,6552,793,3703,171,8003,067,3363,410,3683,538,6443,869,5644,197,1324,531,1374,347,1624,375,6781,383,3101,776,4481,901,8191,381,9501,464,4701,345,0141,957,101618,011856,151918,948764,492712,937643,485438,420490,634239,602208,510261,00697,75087,51485,53258,084208,50617,86927,45025,156-44,39513,898000
       Short-term Investments 
0
0
0
30,497
88,790
101,509
93,894
82,617
38,720
168,535
118,086
280,660
229,726
146,424
548,925
597,914
973,381
931,208
1,390,276
1,068,509
849,167
618,803
375,768
364,728
1,417,097
1,807,744
3,254,300
3,268,725
2,910,472
2,605,452
2,533,617
2,241,962
1,897,783
1,172,554
871,998
665,251
294,057
105,693
106,989
2,600
0
0
0
0
00002,600106,989105,693294,057665,251871,9981,172,5541,897,7832,241,9622,533,6172,605,4522,910,4723,268,7253,254,3001,807,7441,417,097364,728375,768618,803849,1671,068,5091,390,276931,208973,381597,914548,925146,424229,726280,660118,086168,53538,72082,61793,894101,50988,79030,497000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
181,471
29,428
47,347
45,873
42,250
49,668
65,090
58,108
55,912
70,878
77,975
61,663
60,266
79,673
84,010
73,787
129,584
500,175
216,348
192,279
202,645
198,984
332,158
338,140
354,618
395,886
435,294
529,449
603,014
709,106
709,106603,014529,449435,294395,886354,618338,140332,158198,984202,645192,279216,348500,175129,58473,78784,01079,67360,26661,66377,97570,87855,91258,10865,09049,66842,25045,87347,34729,428181,47100000000000000
       Other Current Assets 
0
0
0
2,793
0
3,535
6,867
5,783
4,556
6,135
6,335
4,167
8,702
11,261
17,712
35,623
66,842
94,884
84,485
96,486
104,841
110,773
110,207
90,526
126,594
144,749
151,175
160,319
171,704
225,765
235,345
267,519
266,766
207,716
189,040
216,749
230,157
264,743
253,209
217,006
231,741
273,658
175,113
160,091
160,091175,113273,658231,741217,006253,209264,743230,157216,749189,040207,716266,766267,519235,345225,765171,704160,319151,175144,749126,59490,526110,207110,773104,84196,48684,48594,88466,84235,62317,71211,2618,7024,1676,3356,1354,5565,7836,8673,53502,793000
   > Long-term Assets 
0
0
0
6,433
-44,395
6,765
7,397
10,495
13,446
18,476
25,472
31,414
40,551
55,284
86,729
132,982
123,225
137,149
228,432
305,842
375,502
394,638
445,520
439,593
472,025
510,886
600,654
640,067
680,025
725,077
853,499
1,032,069
1,073,249
1,032,331
976,845
845,946
1,252,457
1,327,317
1,471,337
1,601,861
1,759,931
1,873,157
1,919,124
1,929,317
1,929,3171,919,1241,873,1571,759,9311,601,8611,471,3371,327,3171,252,457845,946976,8451,032,3311,073,2491,032,069853,499725,077680,025640,067600,654510,886472,025439,593445,520394,638375,502305,842228,432137,149123,225132,98286,72955,28440,55131,41425,47218,47613,44610,4957,3976,765-44,3956,433000
       Property Plant Equipment 
0
0
0
5,931
0
6,234
6,541
6,612
7,702
9,752
16,554
25,977
30,723
33,770
55,322
62,568
87,660
96,816
122,265
194,235
306,274
320,723
338,267
313,127
378,224
405,442
443,204
446,298
509,131
538,487
609,768
686,744
624,673
633,100
829,881
845,946
1,053,558
1,144,500
1,289,123
1,389,910
1,549,617
1,620,124
1,712,753
1,657,238
1,657,2381,712,7531,620,1241,549,6171,389,9101,289,1231,144,5001,053,558845,946829,881633,100624,673686,744609,768538,487509,131446,298443,204405,442378,224313,127338,267320,723306,274194,235122,26596,81687,66062,56855,32233,77030,72325,97716,5549,7527,7026,6126,5416,23405,931000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,984
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
0
0
0
0
0
0
0000001091091091091091091091091091091091091091091091091091091091091091091091,98400000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89,281
89,644
143,615
139,771
138,234
128,933
128,933138,234139,771143,61589,64489,28100000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,688
19,715
19,925
19,007
18,928
52,230
6,841
6,509
6,178
52,811
5,563
5,375
5,188
53,731
4,813
12,008
14,104
103,348
45,807
43,325
40,849
94,568
39,735
46,895
53,657
108,855
55,171
53,715
53,939
129,765
129,76553,93953,71555,171108,85553,65746,89539,73594,56840,84943,32545,807103,34814,10412,0084,81353,7315,1885,3755,56352,8116,1786,5096,84152,23018,92819,00719,92519,71519,68800000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
819,888
0
0
0
0
0
0
0
0
00000000819,88800000000000000000000000000000000000
> Total Liabilities 
0
0
0
27,853
0
27,052
35,531
116,764
22,129
31,183
47,593
405,813
68,312
203,803
284,570
362,248
350,205
427,188
425,196
496,037
549,553
579,054
586,833
633,934
1,240,156
1,356,798
1,269,876
1,731,514
1,817,417
1,917,341
1,929,261
2,402,962
2,135,888
2,075,663
2,070,842
1,995,935
1,799,469
1,930,177
1,761,645
2,267,948
2,307,320
2,345,924
2,394,787
2,588,688
2,588,6882,394,7872,345,9242,307,3202,267,9481,761,6451,930,1771,799,4691,995,9352,070,8422,075,6632,135,8882,402,9621,929,2611,917,3411,817,4171,731,5141,269,8761,356,7981,240,156633,934586,833579,054549,553496,037425,196427,188350,205362,248284,570203,80368,312405,81347,59331,18322,129116,76435,53127,052027,853000
   > Total Current Liabilities 
0
0
0
13,371
0
26,114
28,317
35,172
15,826
20,465
29,316
35,058
49,985
49,952
103,161
149,988
141,896
186,435
188,424
246,452
238,809
271,679
265,734
286,044
451,797
365,094
645,721
1,075,199
1,112,542
1,242,314
1,304,435
1,599,555
1,376,306
1,398,409
1,411,311
1,018,020
1,254,551
1,405,109
1,283,297
1,810,113
1,881,689
1,938,768
2,025,332
2,214,899
2,214,8992,025,3321,938,7681,881,6891,810,1131,283,2971,405,1091,254,5511,018,0201,411,3111,398,4091,376,3061,599,5551,304,4351,242,3141,112,5421,075,199645,721365,094451,797286,044265,734271,679238,809246,452188,424186,435141,896149,988103,16149,95249,98535,05829,31620,46515,82635,17228,31726,114013,371000
       Short-term Debt 
0
0
0
322
0
14,049
14,323
14,598
0
0
0
0
2,470
0
9,018
9,222
9,565
9,067
8,736
8,727
18,391
17,907
11,371
10,814
25,895
38,949
63,502
348,910
419,038
451,352
461,016
449,490
430,281
405,517
465,615
353,010
306,353
444,560
351,807
710,316
846,366
869,315
881,510
869,105
869,105881,510869,315846,366710,316351,807444,560306,353353,010465,615405,517430,281449,490461,016451,352419,038348,91063,50238,94925,89510,81411,37117,90718,3918,7278,7369,0679,5659,2229,01802,470000014,59814,32314,0490322000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,561
688,366
826,965
851,657
863,803
851,529
851,529863,803851,657826,965688,366328,56100000000000000000000000000000000000000
       Accounts payable 
0
0
0
2,794
0
4,072
4,301
8,980
3,823
6,071
7,307
11,957
20,482
24,419
35,168
69,779
52,719
85,878
85,552
113,283
105,320
148,536
112,282
122,488
98,364
157,173
146,265
231,957
146,923
168,826
206,203
168,037
236,915
234,355
252,071
294,781
241,360
266,975
341,857
315,111
356,575
333,022
307,532
404,997
404,997307,532333,022356,575315,111341,857266,975241,360294,781252,071234,355236,915168,037206,203168,826146,923231,957146,265157,17398,364122,488112,282148,536105,320113,28385,55285,87852,71969,77935,16824,41920,48211,9577,3076,0713,8238,9804,3014,07202,794000
       Other Current Liabilities 
0
0
0
10,255
0
7,993
9,693
11,594
11,577
14,226
21,715
22,297
24,463
22,427
56,123
61,831
69,723
90,339
92,587
110,524
99,615
95,429
124,482
129,640
296,059
135,960
406,895
459,579
499,356
572,207
588,844
914,972
649,277
719,448
645,081
326,225
644,869
638,014
546,284
731,652
604,195
682,687
786,860
879,963
879,963786,860682,687604,195731,652546,284638,014644,869326,225645,081719,448649,277914,972588,844572,207499,356459,579406,895135,960296,059129,640124,48295,42999,615110,52492,58790,33969,72361,83156,12322,42724,46322,29721,71514,22611,57711,5949,6937,993010,255000
   > Long-term Liabilities 
0
0
0
14,482
0
938
7,214
7,273
6,303
10,718
18,277
17,848
18,327
153,851
181,409
212,260
208,309
240,753
236,772
249,585
310,744
307,375
321,099
347,890
788,359
991,704
624,155
656,315
704,875
675,027
624,826
803,407
759,582
677,254
659,531
977,915
544,918
525,068
478,348
457,835
425,631
407,156
369,455
373,789
373,789369,455407,156425,631457,835478,348525,068544,918977,915659,531677,254759,582803,407624,826675,027704,875656,315624,155991,704788,359347,890321,099307,375310,744249,585236,772240,753208,309212,260181,409153,85118,32717,84818,27710,7186,3037,2737,214938014,482000
> Total Stockholder Equity
0
0
0
25,768
25,768
109,913
100,077
-101,765
243,099
220,047
187,832
352,907
308,417
255,753
750,140
684,231
1,344,381
1,213,197
1,983,431
1,753,647
1,608,769
1,571,264
1,278,478
978,355
2,812,214
2,546,492
4,287,494
3,869,243
4,003,587
3,606,775
3,357,073
6,242,987
5,885,500
5,302,544
4,655,171
4,383,355
4,157,306
3,798,559
3,763,234
3,537,327
3,360,361
3,366,255
3,436,073
3,332,222
3,332,2223,436,0733,366,2553,360,3613,537,3273,763,2343,798,5594,157,3064,383,3554,655,1715,302,5445,885,5006,242,9873,357,0733,606,7754,003,5873,869,2434,287,4942,546,4922,812,214978,3551,278,4781,571,2641,608,7691,753,6471,983,4311,213,1971,344,381684,231750,140255,753308,417352,907187,832220,047243,099-101,765100,077109,91325,76825,768000
   Common Stock
0
0
0
23
0
31
32
12
43
43
43
52
52
52
59
59
70
70
77
77
78
78
78
79
101
102
118
118
119
120
121
133
133
134
135
135
136
137
135
135
136
137
138
138
13813813713613513513713613513513413313312112011911811810210179787878777770705959525252434343123231023000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
100
-53,041
-402
-1,133
-1,809
-1,251
-1,463
-965
-946
-868
-322
38
-480
320
3,114
-724
1,526
6,072
-225
-14,830
-8,001
-6,548
-9,299
-419
6,942
3,204
12,095
12,580
17,950
17,454
-82,450
-161,523
-77,417
-59,014
-143,687
-144,931
-99,446
-131,644
-140,474
-83,525
-148,988
-148,988-83,525-140,474-131,644-99,446-144,931-143,687-59,014-77,417-161,523-82,45017,45417,95012,58012,0953,2046,942-419-9,299-6,548-8,001-14,830-2256,0721,526-7243,114320-48038-322-868-946-965-1,463-1,251-1,809-1,133-402-53,041100000
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
7,941
0
187,250
192,143
-157,857
384,502
385,787
388,568
591,213
597,268
604,603
981,237
1,000,747
1,782,033
1,804,942
2,710,053
2,744,814
2,777,474
2,814,449
2,861,012
2,925,970
5,138,239
5,200,275
7,367,799
7,414,932
7,486,518
7,561,155
7,724,822
11,191,007
11,268,290
11,356,686
11,451,566
11,540,979
11,644,957
11,752,019
11,502,527
11,598,688
11,705,069
11,840,197
11,974,415
12,087,908
12,087,90811,974,41511,840,19711,705,06911,598,68811,502,52711,752,01911,644,95711,540,97911,451,56611,356,68611,268,29011,191,0077,724,8227,561,1557,486,5187,414,9327,367,7995,200,2755,138,2392,925,9702,861,0122,814,4492,777,4742,744,8142,710,0531,804,9421,782,0331,000,747981,237604,603597,268591,213388,568385,787384,502-157,857192,143187,25007,941000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue3,810,241
Cost of Revenue-594,089
Gross Profit3,216,1523,216,152
 
Operating Income (+$)
Gross Profit3,216,152
Operating Expense-3,784,351
Operating Income-568,199-568,199
 
Operating Expense (+$)
Research Development1,953,295
Selling General Administrative1,831,056
Selling And Marketing Expenses-
Operating Expense3,784,3513,784,351
 
Net Interest Income (+$)
Interest Income47,836
Interest Expense--
Other Finance Cost-0
Net Interest Income47,836
 
Pretax Income (+$)
Operating Income-568,199
Net Interest Income47,836
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-533,001-603,397
EBIT - interestExpense = -568,199
-533,001
-644,786
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-568,199-533,001
Earnings Before Interest and Taxes (EBITDA)-396,437
 
After tax Income (+$)
Income Before Tax-533,001
Tax Provision-111,785
Net Income From Continuing Ops-644,786-644,786
Net Income-644,786
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses4,378,440
Total Other Income/Expenses Net35,198-47,836
 

Technical Analysis of Beigene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Beigene. The general trend of Beigene is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Beigene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Beigene Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BeiGene, Ltd..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 267.00 < 284.15 < 287.88.

The bearish price targets are: 196.45 > 187.42 > 172.67.

Know someone who trades $ONC? Share this with them.πŸ‘‡

BeiGene, Ltd. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BeiGene, Ltd.. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BeiGene, Ltd. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BeiGene, Ltd.. The current macd is -0.31481816.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Beigene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Beigene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Beigene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BeiGene, Ltd. Daily Moving Average Convergence/Divergence (MACD) ChartBeiGene, Ltd. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BeiGene, Ltd.. The current adx is 15.78.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Beigene shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
BeiGene, Ltd. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BeiGene, Ltd.. The current sar is 266.25.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BeiGene, Ltd. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BeiGene, Ltd.. The current rsi is 45.07. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
BeiGene, Ltd. Daily Relative Strength Index (RSI) ChartBeiGene, Ltd. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BeiGene, Ltd.. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Beigene price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
BeiGene, Ltd. Daily Stochastic Oscillator ChartBeiGene, Ltd. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BeiGene, Ltd.. The current cci is -53.2781832.

BeiGene, Ltd. Daily Commodity Channel Index (CCI) ChartBeiGene, Ltd. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BeiGene, Ltd.. The current cmo is -16.45010188.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BeiGene, Ltd. Daily Chande Momentum Oscillator (CMO) ChartBeiGene, Ltd. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BeiGene, Ltd.. The current willr is -80.11348981.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
BeiGene, Ltd. Daily Williams %R ChartBeiGene, Ltd. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of BeiGene, Ltd..

BeiGene, Ltd. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BeiGene, Ltd.. The current atr is 11.56.

BeiGene, Ltd. Daily Average True Range (ATR) ChartBeiGene, Ltd. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BeiGene, Ltd.. The current obv is -263,802.

BeiGene, Ltd. Daily On-Balance Volume (OBV) ChartBeiGene, Ltd. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BeiGene, Ltd.. The current mfi is 37.53.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
BeiGene, Ltd. Daily Money Flow Index (MFI) ChartBeiGene, Ltd. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BeiGene, Ltd..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

BeiGene, Ltd. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BeiGene, Ltd. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.065
Ma 20Greater thanMa 50242.306
Ma 50Greater thanMa 100249.326
Ma 100Greater thanMa 200228.949
OpenGreater thanClose236.280
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Beigene with someone you think should read this too:
  • Are you bullish or bearish on Beigene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Beigene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BeiGene, Ltd.

I send you an email if I find something interesting about BeiGene, Ltd..


Comments

How you think about this?

Leave a comment

Stay informed about BeiGene, Ltd..

Receive notifications about BeiGene, Ltd. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.